Organization
Institute for Pathology
5 abstracts
Abstract
Surgical outcomes of patients with resectable non-small-cell lung cancer receiving neoadjuvant immunotherapy with nivolumab plus relatlimab or nivolumab: Findings from the prospective, randomized, multicentric phase II study NEOpredict-Lung.Org: West German Cancer Center, University Hospital Essen, Jessa Hospital, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Department of Pathology and Neuropathology,
Abstract
Multiomic factor analysis for pathologic complete response (pCR) after 12 weeks of pembrolizumab + trastuzumab + pertuzumab in HER2-enriched (HER2-E) early breast cancer (eBC) in the Keyriched-1 trial.Org: West German Study Group, Moenchengladbach, Germany, Queen Mary University of London, London, United Kingdom, Medical School Brandenburg, Institute for Biometrics and Registry Research, Neuruppin, Neuruppin, Germany,
Abstract
Presence of CD8+ cytotoxic T-cells in proximity to tumor cells, TIM3, CTLA-4 and prognostic implications for muscle-invasive urothelial cancer.Org: University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Charité Berlin, Berlin, Germany, Charité Universitätsmedizin Berlin,
Abstract
Clinical characteristics and treatment outcome of patients with advanced non-small-cell lung cancer (NSCLC) and FGFR fusions.Org: University of Cologne, University Hospital Cologne Center for Integrated Oncology, Institute for Pathology, Department of Translational Genomics, Network Genomic Medicine,
Abstract
EGFR expression and relapse in patients with melanoma receiving adjuvant PD-1-based immunotherapy.Org: Skin Cancer Center, University Hospital Leipzig, Department of Dermatology, Eberhard Karls University of Tuebingen, Tübingen, Germany, Kantonsspital St. Gallen,